INCB-081776
- Generic Name
- INCB-081776
Pembrolizumab, INCB081776, and Radiation Therapy for Head and Neck Squamous Cell Carcinoma
Early Phase 1
Recruiting
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2024-03-13
- Last Posted Date
- 2025-02-18
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 12
- Registration Number
- NCT06308913
- Locations
- 🇺🇸
UW Carbone Cancer Center, Madison, Wisconsin, United States
A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies
Phase 1
Active, not recruiting
- Conditions
- Advanced Solid Tumors
- Interventions
- First Posted Date
- 2018-05-11
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 84
- Registration Number
- NCT03522142
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath